


SEEING NONMELANOMA SKIN CANCERS THROUGH A NEW LENS: THE ROLE AND PLACE OF IMMUNOTHERAPY



IMMUNOTHERAPY INDICATIONS IN CSCC

WHAT?	WHERE?	WHICH?	WHEN?	HOW?
CEMPIPLIMAB	EU and USA	<ul style="list-style-type: none"> Locally advanced Metastatic 	Non-candidacy for curative surgery or curative RT	350 mg IV Q3W
PEMBROLIZUMAB	USA	<ul style="list-style-type: none"> Locally advanced Metastatic Recurrent 	Not curable by surgery or RT	200 mg IV Q3W or 400 mg IV Q6W

SNAPSHOT: IMMUNOTHERAPY EFFICACY



MANAGING IMMUNE-RELATED ADVERSE EVENTS

TUMOR CRITERIA		PATIENT CRITERIA		HISTORY CRITERIA	
Deep invasion	Large size	Patient willingness	Patient health and comorbidities	Multiple recurrences	Prior surgery
Multiple/agminated lesions without defined borders	Critically or functionally significant area	Patient age	Prior radiotherapy		
Inadequate excision margins	Surgical complexity (large size, site of lesion)				

Cemiplimab, EMA EPAR, product information. Updated 2/4/2022; Cemiplimab. FDA prescribing information. Issued 2/22/2021; Pembrolizumab. FDA prescribing information. Issued 3/21/22; Rischin D, et al. EADO 2021. Abstract P-236; Rischin D, et al. ESMO 2021. Abstract 1066P; Hughes BGM, et al. *Ann Oncol.* 2021;32(10):1276-1285; Maubec E, et al. *J Clin Oncol.* 2020;38(26):3051-3061; Argenziano G, et al. *Ther Adv Med Oncol.* 2022;14:17588359211066272. eCollection 2022.





INDICATIONS FOR SYSTEMIC THERAPY IN BCC


WHAT?	WHERE?	WHICH?	WHEN?	HOW?
SONIDEGIB	EU	➔ Locally advanced	Not amenable to curative surgery or curative RT Recurrence after surgery or RT, or non-candidacy for surgery or RT	200 mg PO QD
	USA			
VISMODEGIB	EU	➔ Locally advanced	Symptomatic metastatic disease, or locally advanced disease inappropriate for surgery or RT Metastatic, or locally advanced post-surgical recurrence or non-candidacy for surgery or RT	150 mg PO QD
	USA	➔ Metastatic		
CEMIPLIMAB	EU	➔ Locally advanced	Prior HHI or HHI is not appropriate Progression on HHI or HHI intolerance	350 mg IV Q3W
	USA	➔ Metastatic		



EMPOWER BCC-1: CEMIPIMAB EFFICACY



MANAGING IMMUNE-RELATED ADVERSE EVENTS



Sonidegib. EMA EPAR. Updated 4/26/2021; Sonidegib. FDA prescribing information. Updated 5/13/2019; Vismodegib EMA EPAR. Updated 7/29/2021; Vismodegib FDA prescribing information. Updated 7/31/2020; Cemiplimab, EMA EPAR. Updated 2/4/2022; Cemiplimab. FDA prescribing information. Updated 2/22/2021; Stratigos AJ, et al. *Lancet Oncol.* 2021;22(6):848-857; Lewis KD, et al. SITC 2020; Poster 428; Damsin T, et al. *Expert Rev Anticancer Ther.* 2022 Mar;22(3):243-248. Ramos-Casals M, et al. *Nat Rev Dis Primers.* 2020;6(1):38.